Rheumatoid Arthritis Brands Missing Key Opportunities to Better Engage Patients and HCPs Through Digital Channels

    Rheumatoid Arthritis Brands Missing Key Opportunities to Better Engage                   Patients and HCPs Through Digital Channels  Leveraging Nurse Support Could Boost Engagement with Rheumatoid Arthritis Brands, According to Findings in New Manhattan Research Analysis from Decision Resources Group  PR Newswire  BURLINGTON, Mass., June 3, 2014  BURLINGTON, Mass., June 3, 2014 /PRNewswire/ --Manhattan Research's new Digital Competitive Landscape analysis finds that many rheumatoid arthritis (RA) brands are overlooking valuable ways to reach patients and physicians through digital channels and support their evolving needs. Each opportunity represents a risk in a highly competitive market.  Decision Resources Group Logo  Key findings from the Digital Competitive Landscape for RA analysis:    oNurse support is underleveraged: Thirty-nine percent of online RA patients     are interested in accessing pharma-sponsored nurse support on pharma     websites, but just over half of brands tracked offer this service. Nurse     support is only offered on product websites, even though online consumers     suffering from RA are engaged with pharma-sponsored condition websites.   oCurrent condition tracking tools are basic: Though most pharma RA websites     have some kind of symptom or condition tracking resource, current     offerings are relatively basic and don't fully leverage technology for     trending, aggregating or sharing symptoms and progress. Online RA patients     are more likely to use a computer than pen and paper to track their health     and wellness, and condition tracking and management tools are one of the     top resources that this patient segment wants from pharma websites.   oRA Healthcare Professional (HCP) product websites are underperforming in     mobile: Seventy-six percent of rheumatologists with smartphones use them     to access professional websites, yet only half of HCP RA product websites     are mobile optimized. Moreover, most mobile optimized RA HCP websites     score poorly for mobile speed performance on Google's PageSpeed Insights     tool – giving further indication that the category overall is underserving     HCPs on mobile devices.  Comments from Decision Resources Group Vice President of Research Monique Levy:    o"Pharma brands are becoming much more aggressive in terms of finding and     executing on competitive digital marketing opportunities and having a more     disciplined multichannel strategic approach. The good news is that there     are plenty of easy wins there for the taking this year and this deep     patient journey and digital engagement analysis powerfully illuminates the     way forward."  Additional Resources:    oRequest a recording of Manhattan Research's Digital Brand Planning     Webinar, focusing on how pharma clients can shape and refine their digital     brand strategy with data, analysis and insights. Learn more.  Sources: Digital Competitive Landscape: Rheumatoid Arthritis; ePharma Consumer® 2013: Rheumatoid Arthritis Patients; Taking the Pulse® U.S. 2014: Rheumatologists, Google PageSpeed Insights tool (accessed May 24, 2014)  Digital Competitive Landscape: Rheumatoid Arthritis    - 25 websites analyzed, as well as other brand digital assets   - Digital initiatives from:       oBrands: Enbrel, Orencia, Rituxan, Humira, Actemra, Remicade, Simponi,        Cimzia, Kineret, Xeljanz      oCompanies: Amgen, Bristol-Myers Squibb, AbbVie, UCB, Genentech, Biogen,        Sobi, Pfizer, Janssen    - Digital properties, tactics and channels such as website features and   content, serviceportals. mobile, video, support programs, communication   with reps, and much more  About Digital Competitive Landscape Series Manhattan Research analysts track, categorize and analyze pharma website features, apps, social media, and other digital investments for competitive insights across 30+ brand categories, including RA, psoriasis, multiple sclerosis, diabetes, and many more. Paired with extensive research on consumer and HCP digital behavior and interest in pharma resources, expert analysts give you actionable answers to your strategic marketing questions. Learn more.  About Decision Resources GroupDecision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Decision Resources Group's Manhattan Research product line offers insights and analysis on digital health trends among healthcare professionals and consumers in the Americas, Europe and Asia-Pacific. Find out more at www.manhattanresearch.com and www.DecisionResourcesGroup.com.  All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.  For more information, contact:  Decision Resources Group Christopher Comfort 781-993-2597 ccomfort@dresourcesgroup.com  Logo- http://photos.prnewswire.com/prnh/20130103/MM36768LOGO  SOURCE Decision Resources Group  Website: http://www.decisionresourcesgroup.com  
Press spacebar to pause and continue. Press esc to stop.